OREANDA-NEWS. August 18, 2015. To date, Spiolto® Respimat® has gained approval in more than 20 EU/EEA countries, the US, Canada and Australia for use in the treatment of patients with COPD.

Spiolto® Respimat® is built on tiotropium, the active ingredient in Spiriva® - the world’s most prescribed COPD maintenance treatment with over 40 million patient years of real life experience across all COPD severities.5 It is enhanced by olodaterol††, a unique and effective long-acting beta2-agonist with a fast onset of action,6 specifically designed to complement the efficacy of Spiriva®. Spiolto® is delivered by Respimat®, the only inhaler available that actively‡‡ delivers a unique mist, meaning the patient just needs to breathe in naturally for the medication to go deep into the lungs.7-13

About COPD
COPD is a chronic, progressive, treatable, but incurable lung disease that affects 210 million people worldwide.14 It is a growing world health priority and the World Health Organization predicts it will become the 3rd leading cause of death by 2030.15

For people with COPD, decreasing lung function causes breathlessness and stops them from being active. This can lead to a downward spiral of worsening symptoms and even further inactivity,16 contributing to an increased risk of disability and death.17

When the majority of patients first go to see their doctor, their disease has already progressed18 to a point when they need maintenance treatment.19 For most patients at this point§§, lung function is declining at its fastest rate – quicker than in the later stages of the disease.20 Optimal management right from the start of maintenance therapy may give patients the best opportunity to manage their symptoms, stay active and maintain a good quality of life for as long as possible.